FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2923925844> ?p ?o ?g. }

• W2923925844 endingPage "55" @default.
• W2923925844 startingPage "46" @default.
• W2923925844 abstract "The aim of the investigation was to study the changes of cytokine profile parameters in patients with rheumatoid arthritis (RA) 12 and 24 weeks after initiation of therapy with rituximab (RTM) biosimilar at a total dose of 1200 mg, in comparison with the original drug Material and methods. The study included 54 patients with a reliable diagnosis of RA. Depending on the therapy, all patients were divided into two groups: 34 patients received the original RTM (group 1) and 20 patients – biosimilar (group 2) in a total dose of 1200 mg according to the standard scheme. The concentration of 27 cytokines in blood serum was determined by multiplex xMAP technology on the analyzer Bio-Plex Array System (BIO-RAD, USA). Results and discussion. The use of the original drug has been accompanied by reliable and significant reduction (over 30%) by 24 weeks of treatment levels of proinflammatory [interleukin (IL) 1â, IL2, IL6, IL12, IL15, interferon ã (IFN-ã), tumor necrosis factor á (TNF-á)], IL1 receptor antagonist (IL1ra), IL5, IL9, IL10, IL13 cytokines, growth factors (IL7, granulocyte-macrophage colony stimulating factor, fibroblast growth factor) and chemokines (monocyte chemoattractant protein 1 – MCP1). During the treatment with Acellbia a rapid and marked reduction in the concentration of practically the whole range of investigated parameters already 12–24 weeks after the first infusion was achieved. After 24 weeks a decrease in the concentration IL1â, IL1ra, IL2, IL4, IL5, IL6, IL7, IL8, IL9, IL10, IL12, IL13, IL15, IL17, eotaxin, granulocyte colony-stimulating factor, IFN-ã, IFN-ã-induced protein 10, MCP1, macrophage inflammation protein 1â, TNF-á, vascular endothelial growth factor was recorded (p<0.05). Conclusion. Analysis of the effectiveness of two infusions of RTM biosimilar Acellbia («BIOCAD», Russia) 24 weeks after the start of therapy shows its ability to cause a decrease of levels of proinflammatory cytokines, chemokines and growth factors in the blood serum. Changes of the cytokine profile during the therapy with Acellbia are not significantly different from that during the treatment with the original drug." @default.
• W2923925844 created "2019-04-01" @default.
• W2923925844 creator A5001854360 @default.
• W2923925844 creator A5013375711 @default.
• W2923925844 creator A5020360506 @default.
• W2923925844 creator A5074452337 @default.
• W2923925844 creator A5091101613 @default.
• W2923925844 date "2019-03-20" @default.
• W2923925844 modified "2023-10-06" @default.
• W2923925844 title "Changes of cytokine profile measures during the treatment of rheumatoid arthritis with rituximab biosimilar (Acellbia, BIOCAD) and the original drug (MabThera, F. Hoffmann-La Roche Ltd., Switzerland)" @default.
• W2923925844 cites W1499640956 @default.
• W2923925844 cites W1518558591 @default.
• W2923925844 cites W182878407 @default.
• W2923925844 cites W2001710332 @default.
• W2923925844 cites W2009914831 @default.
• W2923925844 cites W2027245742 @default.
• W2923925844 cites W2037550429 @default.
• W2923925844 cites W2043724494 @default.
• W2923925844 cites W2046188285 @default.
• W2923925844 cites W2067691287 @default.
• W2923925844 cites W2084001707 @default.
• W2923925844 cites W2100645101 @default.
• W2923925844 cites W2102259929 @default.
• W2923925844 cites W2102697241 @default.
• W2923925844 cites W2105132195 @default.
• W2923925844 cites W2110826367 @default.
• W2923925844 cites W2126894693 @default.
• W2923925844 cites W2129536136 @default.
• W2923925844 cites W2135735584 @default.
• W2923925844 cites W2141301927 @default.
• W2923925844 cites W2141511965 @default.
• W2923925844 cites W2143953826 @default.
• W2923925844 cites W2155779547 @default.
• W2923925844 cites W2159705610 @default.
• W2923925844 cites W2169228864 @default.
• W2923925844 cites W2172216105 @default.
• W2923925844 cites W2205046347 @default.
• W2923925844 cites W2221126191 @default.
• W2923925844 cites W2411832526 @default.
• W2923925844 cites W2519049669 @default.
• W2923925844 cites W2552308644 @default.
• W2923925844 cites W2560673112 @default.
• W2923925844 cites W2594852036 @default.
• W2923925844 cites W2735286418 @default.
• W2923925844 cites W2769516143 @default.
• W2923925844 cites W2793407472 @default.
• W2923925844 cites W2793614980 @default.
• W2923925844 cites W2802364203 @default.
• W2923925844 cites W2883406108 @default.
• W2923925844 cites W60759546 @default.
• W2923925844 doi "https://doi.org/10.14412/1995-4484-2019-46-55" @default.
• W2923925844 hasPublicationYear "2019" @default.
• W2923925844 type Work @default.
• W2923925844 sameAs 2923925844 @default.
• W2923925844 citedByCount "3" @default.
• W2923925844 countsByYear W29239258442019 @default.
• W2923925844 countsByYear W29239258442020 @default.
• W2923925844 countsByYear W29239258442022 @default.
• W2923925844 crossrefType "journal-article" @default.
• W2923925844 hasAuthorship W2923925844A5001854360 @default.
• W2923925844 hasAuthorship W2923925844A5013375711 @default.
• W2923925844 hasAuthorship W2923925844A5020360506 @default.
• W2923925844 hasAuthorship W2923925844A5074452337 @default.
• W2923925844 hasAuthorship W2923925844A5091101613 @default.
• W2923925844 hasBestOaLocation W29239258441 @default.
• W2923925844 hasConcept C126322002 @default.
• W2923925844 hasConcept C149892131 @default.
• W2923925844 hasConcept C170493617 @default.
• W2923925844 hasConcept C17991360 @default.
• W2923925844 hasConcept C187316574 @default.
• W2923925844 hasConcept C203014093 @default.
• W2923925844 hasConcept C2776885963 @default.
• W2923925844 hasConcept C2777575956 @default.
• W2923925844 hasConcept C2778122271 @default.
• W2923925844 hasConcept C2778690821 @default.
• W2923925844 hasConcept C71924100 @default.
• W2923925844 hasConceptScore W2923925844C126322002 @default.
• W2923925844 hasConceptScore W2923925844C149892131 @default.
• W2923925844 hasConceptScore W2923925844C170493617 @default.
• W2923925844 hasConceptScore W2923925844C17991360 @default.
• W2923925844 hasConceptScore W2923925844C187316574 @default.
• W2923925844 hasConceptScore W2923925844C203014093 @default.
• W2923925844 hasConceptScore W2923925844C2776885963 @default.
• W2923925844 hasConceptScore W2923925844C2777575956 @default.
• W2923925844 hasConceptScore W2923925844C2778122271 @default.
• W2923925844 hasConceptScore W2923925844C2778690821 @default.
• W2923925844 hasConceptScore W2923925844C71924100 @default.
• W2923925844 hasIssue "1" @default.
• W2923925844 hasLocation W29239258441 @default.
• W2923925844 hasLocation W29239258442 @default.
• W2923925844 hasOpenAccess W2923925844 @default.
• W2923925844 hasPrimaryLocation W29239258441 @default.
• W2923925844 hasRelatedWork W1971296504 @default.
• W2923925844 hasRelatedWork W1994050787 @default.
• W2923925844 hasRelatedWork W2006549602 @default.
• W2923925844 hasRelatedWork W2009750871 @default.
• W2923925844 hasRelatedWork W2023834531 @default.
• W2923925844 hasRelatedWork W2156016155 @default.

• next